Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation?
- PMID: 16335791
- DOI: 10.1007/s11010-005-1083-y
Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation?
Abstract
Recent mining of the human and mouse genomes, use of yeast genetics, and detailed analyses of several biochemical pathways, have resulted in the identification of many new roles for ubiquitin-proteasome mediated degradation of proteins. In the context of last year's award of Noble Prize (Chemistry) work, the ubiquitin and ubiquitin-like modifications are increasingly recognized as key regulatory events in health and disease. Although the ATP-dependent ubiquitin-proteasome system has evolved as premier cellular proteolytic machinery, dysregulation of this system by several different mechanisms leads to inappropriate degradation of specific proteins and pathological consequences. While aberrations in the ubiquitin-proteasome pathway have been implicated in certain malignancies and neurodegenerative disorders, recent studies indicate a role for this system in the pathogenesis of diabetes and its complications. Inappropriate degradation of insulin signaling molecules such as insulin receptor substrates (IRS-1 and IRS-2) has been demonstrated in experimental diabetes, mediated in part through the up-regulation of suppressors of cytokine signaling (SOCS). It appears that altered ubiquitin-proteasome system might be one of the molecular mechanisms of insulin resistance in many pathological situations. Drugs that modulate the SOCS action and/or proteasomal degradation of proteins could become novel agents for the treatment of insulin resistance and Type 2 diabetes.
Similar articles
-
The ubiquitin-proteasome pathway is a new partner for the control of insulin signaling.Curr Opin Clin Nutr Metab Care. 2004 May;7(3):249-54. doi: 10.1097/00075197-200405000-00002. Curr Opin Clin Nutr Metab Care. 2004. PMID: 15075914 Review.
-
The role of ubiquitin-proteasome system in ageing.Gen Comp Endocrinol. 2011 May 15;172(1):39-43. doi: 10.1016/j.ygcen.2011.02.005. Epub 2011 Feb 13. Gen Comp Endocrinol. 2011. PMID: 21324320 Review.
-
Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency.Endocrinology. 2008 Nov;149(11):5384-90. doi: 10.1210/en.2008-0132. Epub 2008 Jul 24. Endocrinology. 2008. PMID: 18653708 Free PMC article.
-
[Degradation of proteins by ubiquitin proteasome pathway].Klin Onkol. 2013;26(4):251-6. doi: 10.14735/amko2013251. Klin Onkol. 2013. PMID: 23961855 Review. Czech.
-
Insulin/insulin-like growth factor (IGF) stimulation abrogates an association between a deubiquitinating enzyme USP7 and insulin receptor substrates (IRSs) followed by proteasomal degradation of IRSs.Biochem Biophys Res Commun. 2012 Jun 22;423(1):122-7. doi: 10.1016/j.bbrc.2012.05.093. Epub 2012 May 23. Biochem Biophys Res Commun. 2012. PMID: 22634009
Cited by
-
Glycaemic control improves perfusion recovery and VEGFR2 protein expression in diabetic mice following experimental PAD.Cardiovasc Res. 2014 Mar 1;101(3):364-72. doi: 10.1093/cvr/cvt342. Epub 2014 Jan 2. Cardiovasc Res. 2014. PMID: 24385342 Free PMC article.
-
A peripheral blood transcriptomic signature predicts autoantibody development in infants at risk of type 1 diabetes.JCI Insight. 2018 Mar 8;3(5):e98212. doi: 10.1172/jci.insight.98212. JCI Insight. 2018. PMID: 29515040 Free PMC article.
-
Role of transcription factor modifications in the pathogenesis of insulin resistance.Exp Diabetes Res. 2012;2012:716425. doi: 10.1155/2012/716425. Epub 2011 Oct 26. Exp Diabetes Res. 2012. PMID: 22110478 Free PMC article. Review.
-
RING finger protein 10 is a potential drug target for diabetic vascular complications.Mol Med Rep. 2019 Aug;20(2):931-938. doi: 10.3892/mmr.2019.10358. Epub 2019 Jun 6. Mol Med Rep. 2019. PMID: 31173254 Free PMC article.
-
Distinct regulation of IRS proteins in adipose tissue from obese aged and dexamethasone-treated rats.Endocrine. 2006 Jun;29(3):391-8. doi: 10.1385/ENDO:29:3:391. Endocrine. 2006. PMID: 16943575
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical